Plasma Fractionation Market - Distribution by Type of Company (In-house Manufacturers and Contract Service Providers), Scale of Operation (Preclinical, Clinical and Commercial), Type of Plasma-derived Therapeutic Products Manufactured (Albumins, Coagulation Factors, Immunoglobulins, Protease Inhibitors and Other Plasma derived Products), Therapeutic Areas of Plasma-derived Products (Hematological Disorders, Hepatic Disorders, Immunological Disorders, Neurological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global plasma fractionation market is estimated to be USD 12.7 billion by 2035 and anticipated to grow at a CAGR of 10% during the forecast period 2023-2035.
In the past twenty years, the number of people affected by rare diseases has notably risen, now impacting over 410 million individuals globally with chronic disorders. This surge in cases has led to a greater need for plasma-derived therapies, which have shown significant effectiveness in treating these conditions. Meeting this growing demand requires a consistent and strong supply of blood plasma. Currently, the United States is a central hub for plasma donation centers, housing around 80% of the world's facilities dedicated to plasma donation. Impressively, this country contributes over 70% of the plasma used by plasma fractionators to produce these therapies. Plasma fractionation is vital in separating and refining essential components within blood plasma, such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These refined blood plasma components form the basis for developing therapeutic treatments.
A recent development in April 2023 involved the approval of HYQVIA, a recombinant immunoglobulin, for expanded use in treating primary immunodeficiency in children aged 2 to 16 years. Plasma-derived therapies are crucial in saving lives, especially for those dealing with rare and complex diseases globally. Recognizing the growing need for these critical medicines, ongoing advancements in blood plasma fractionation and manufacturing technology are expected to ensure timely access for those in need in the future. This progress will be instrumental in meeting the increasing demand for plasma-derived therapies amid the rising prevalence of rare and complex diseases.
Report Coverage
In the past twenty years, the number of people affected by rare diseases has notably risen, now impacting over 410 million individuals globally with chronic disorders. This surge in cases has led to a greater need for plasma-derived therapies, which have shown significant effectiveness in treating these conditions. Meeting this growing demand requires a consistent and strong supply of blood plasma. Currently, the United States is a central hub for plasma donation centers, housing around 80% of the world's facilities dedicated to plasma donation. Impressively, this country contributes over 70% of the plasma used by plasma fractionators to produce these therapies. Plasma fractionation is vital in separating and refining essential components within blood plasma, such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These refined blood plasma components form the basis for developing therapeutic treatments.
A recent development in April 2023 involved the approval of HYQVIA, a recombinant immunoglobulin, for expanded use in treating primary immunodeficiency in children aged 2 to 16 years. Plasma-derived therapies are crucial in saving lives, especially for those dealing with rare and complex diseases globally. Recognizing the growing need for these critical medicines, ongoing advancements in blood plasma fractionation and manufacturing technology are expected to ensure timely access for those in need in the future. This progress will be instrumental in meeting the increasing demand for plasma-derived therapies amid the rising prevalence of rare and complex diseases.
Report Coverage
- The report investigates the plasma fractionation market across several parameters: type of company, scale of operation, type of plasma-derived therapeutic products manufactured, therapeutic areas of plasma-derived products and key geographical regions
- It assesses market growth influencers such as drivers, restraints, opportunities, and challenges, analyzing their impact.
- Evaluation of market advantages and obstacles is provided, along with insights into the competitive landscape for key market players.
- Revenue forecasts for market segments are detailed across four major regions.
- An executive summary encapsulates research insights on the current status and anticipated future trends in the plasma fractionation market, covering its components, collection and screening processes, applications, challenges, and the role of third-party service providers. The summary delves into future prospects in this domain.
- A comprehensive evaluation of the plasma fractionation market landscape involves analyzing companies based on criteria such as establishment year, workforce size, headquarters location, business type (in-house manufacturers, contract service providers), site of fractionation and collection facilities, patented technology presence, additional capabilities (formulation, testing), operational scale, manufactured plasma-derived therapeutic products, therapeutic areas targeted, and end-user demographics.
- A meticulous competitive analysis focuses on plasma fractionation companies across North America, Europe, Asia-Pacific, and other regions. Companies are categorized by type (in-house manufacturers, combined manufacturers, service providers) and evaluated based on parameters including experience, facility accreditations, plasma collection infrastructure, proprietary technologies, product portfolios, operational scale, therapeutic focus, and target consumer base.
- Detailed tabular profiles of key plasma fractionation companies across North America, Europe, and Asia-Pacific are presented, encompassing company overviews, financial data (if available), fractionation portfolios, recent developments, and anticipated future trajectories.
- An analysis of recent partnerships and collaborations in plasma fractionation, plasma-derived therapies, and associated technologies post-2018. Parameters include partnership types, objectives (collection, purification, fractionation), plasma-derived product categories, partner types (industry, non-industry), and active participants, with regional distribution of engaged companies.
- An in-depth examination of expansions undertaken by diverse companies since 2018 to enhance their plasma fractionation capabilities. Analysis includes expansion timelines, types (capacity, new facilities), facility categorization (collection, fractionation), facility locations, manufactured plasma-derived products, and key contributors.
- Detailed analysis of global fractionation capacity based on publicly available information and insights from primary and secondary research. This examination highlights capacity distribution based on company size, manufactured plasma-derived therapeutic products, operational scale, and geographic regions (North America, Europe, Asia-Pacific, and others).
- Baxter
- Grifols
- Kedrion
- Octapharma
- CSL
- Takeda Pharmaceutical
1. PREFACE
1.1. Plasma Fractionation Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Blood Plasma
3.2.1. Plasma Collection
3.2.2. Plasma Screening
3.2.3. Plasma Fractionation
3.3. Applications of Plasma Fractionation
3.4. Challenges Associated with Plasma Fractionation
3.5. Need for Third-party Service Providers
3.5.1. Overview of Third-party Service Providers
3.6. Future Perspectives
4. PLASMA FRACTIONATION: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Plasma Fractionation: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region)
4.2.4. Analysis by Location of Headquarters (Country)
4.2.5. Analysis by Year of Establishment and Location of Headquarters (Region)
4.2.6. Analysis by Company Size and Location of Headquarters (Region)
4.2.7. Analysis by Type of Company
4.2.8. Analysis by Location of Plasma Fractionation Facilities (Region)
4.2.9. Analysis by Location of Plasma Collection Facility
4.2.10. Analysis by Availability of Patented / Proprietary Technology
4.2.11. Analysis by Additional Fractionation Capabilities
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
4.2.14. Analysis by Therapeutic Areas of Plasma-derived Products
4.2.15. Analysis by End Users
4.2.16. Information on Plasma Fractionation Capacity and Accreditation / Certification
4.2.17. Information on Upcoming Plasma Fractionation Facilities
4.2.18. Information on Companies Previously Involved in Plasma Fractionation
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: In-house Manufacturers
5.4.1. Players based in North America and Europe
5.4.2. Players based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers
5.5.1. Players based in North America and Europe
5.5.2. Players based in Asia-Pacific and Rest of the World
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Baxter
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Plasma Fractionation Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.3. Companies Headquartered in Europe
6.3.1. Grifols
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Plasma Fractionation Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Kedrion
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Plasma Fractionation Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Octapharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Plasma Fractionation Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.4. Companies Headquartered in Asia-Pacific
6.4.1. CSL
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Plasma Fractionation Portfolio
6.4.1.5. Recent Developments and Future Outlook
6.4.2. Takeda Pharmaceutical
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Plasma Fractionation Portfolio
6.4.2.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Plasma Fractionation: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Purpose of Agreement
7.3.5. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
7.3.6. Analysis by Type of Partner
7.3.7. Analysis by Year of Partnership and Type of Partner
7.3.8. Analysis by Type of Partnership and Type of Partner
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.4. Analysis by Geography
7.4.1. Local and International Agreements
7.4.2. Intracontinental and Intercontinental Agreements
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Expansion Models
8.3. Plasma Fractionation: Recent Expansions
8.3.1. Analysis by Year of Expansion
8.3.2. Analysis by Type of Expansion
8.3.3. Analysis by Year and Type of Expansion
8.3.4. Analysis by Type of Facility
8.3.5. Analysis by Location of Expanded Facility
8.3.6. Analysis by Year and Location of Expanded Facility
8.3.7. Analysis by Plasma-derived Therapeutic Products Manufactured
8.3.8. Most Active Players: Analysis by Number of Expansions
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.2.1. Annual Plasma Fractionation Capacity
9.2.1.1. Analysis by Company Size
9.2.1.2. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
9.2.1.3. Analysis by Scale of Operation
9.2.2. Analysis by Location of Plasma Fractionation Facility
9.2.3 .Analysis by Location of Headquarters
9.3. Concluding Remarks
10. MARKET SIZING AND OPPURTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035
10.3.1. Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035
10.3.1.1. Plasma Fractionation Market for In-house Manufacturers, 2023-2035
10.3.1.2. Plasma Fractionation Market for Contract Service Providers, 2023-2035
10.3.2. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035
10.3.2.1. Plasma Fractionation Market for Preclinical, 2023-2035
10.3.2.2. Plasma Fractionation Market for Clinical, 2023-2035
10.3.2.3. Plasma Fractionation Market for Commercial, 2023-2035
10.3.3. Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035
10.3.3.1. Plasma Fractionation Market for Albumins, 2023-2035
10.3.3.2. Plasma Fractionation Market for Coagulation Factors, 2023-2035
10.3.3.3. Plasma Fractionation Market for Immunoglobulins, 2023-2035
10.3.3.4. Plasma Fractionation Market for Protease Inhibitors, 2023-2035
10.3.3.5. Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035
10.3.4. Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035
10.3.4.1. Plasma Fractionation Market for Hematological Disorders, 2023-2035
10.3.4.2. Plasma Fractionation Market for Hepatic Disorders, 2023-2035
10.3.4.3. Plasma Fractionation Market for Immunological Disorders, 2023-2035
10.3.4.4. Plasma Fractionation Market for Neurological Disorders, 2023-2035
10.3.4.5. Plasma Fractionation Market for Other Disorders, 2023-2035
10.3.5. Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035
10.3.5.1. Plasma Fractionation Market in North America, 2023-2035
10.3.5.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.5.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.5.4. Plasma Fractionation Market in Rest of the World, 2023-2035
10.3.6. Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035
10.3.6.1. Plasma Fractionation Market in North America, 2023-2035
10.3.6.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.6.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.6.4. Plasma Fractionation Market in Rest of the World, 2023-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Plasma Fractionation Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Blood Plasma
3.2.1. Plasma Collection
3.2.2. Plasma Screening
3.2.3. Plasma Fractionation
3.3. Applications of Plasma Fractionation
3.4. Challenges Associated with Plasma Fractionation
3.5. Need for Third-party Service Providers
3.5.1. Overview of Third-party Service Providers
3.6. Future Perspectives
4. PLASMA FRACTIONATION: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Plasma Fractionation: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region)
4.2.4. Analysis by Location of Headquarters (Country)
4.2.5. Analysis by Year of Establishment and Location of Headquarters (Region)
4.2.6. Analysis by Company Size and Location of Headquarters (Region)
4.2.7. Analysis by Type of Company
4.2.8. Analysis by Location of Plasma Fractionation Facilities (Region)
4.2.9. Analysis by Location of Plasma Collection Facility
4.2.10. Analysis by Availability of Patented / Proprietary Technology
4.2.11. Analysis by Additional Fractionation Capabilities
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
4.2.14. Analysis by Therapeutic Areas of Plasma-derived Products
4.2.15. Analysis by End Users
4.2.16. Information on Plasma Fractionation Capacity and Accreditation / Certification
4.2.17. Information on Upcoming Plasma Fractionation Facilities
4.2.18. Information on Companies Previously Involved in Plasma Fractionation
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: In-house Manufacturers
5.4.1. Players based in North America and Europe
5.4.2. Players based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers
5.5.1. Players based in North America and Europe
5.5.2. Players based in Asia-Pacific and Rest of the World
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Baxter
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Plasma Fractionation Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.3. Companies Headquartered in Europe
6.3.1. Grifols
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Plasma Fractionation Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Kedrion
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Plasma Fractionation Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Octapharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Plasma Fractionation Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.4. Companies Headquartered in Asia-Pacific
6.4.1. CSL
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Plasma Fractionation Portfolio
6.4.1.5. Recent Developments and Future Outlook
6.4.2. Takeda Pharmaceutical
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Plasma Fractionation Portfolio
6.4.2.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Plasma Fractionation: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Purpose of Agreement
7.3.5. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
7.3.6. Analysis by Type of Partner
7.3.7. Analysis by Year of Partnership and Type of Partner
7.3.8. Analysis by Type of Partnership and Type of Partner
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.4. Analysis by Geography
7.4.1. Local and International Agreements
7.4.2. Intracontinental and Intercontinental Agreements
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Expansion Models
8.3. Plasma Fractionation: Recent Expansions
8.3.1. Analysis by Year of Expansion
8.3.2. Analysis by Type of Expansion
8.3.3. Analysis by Year and Type of Expansion
8.3.4. Analysis by Type of Facility
8.3.5. Analysis by Location of Expanded Facility
8.3.6. Analysis by Year and Location of Expanded Facility
8.3.7. Analysis by Plasma-derived Therapeutic Products Manufactured
8.3.8. Most Active Players: Analysis by Number of Expansions
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.2.1. Annual Plasma Fractionation Capacity
9.2.1.1. Analysis by Company Size
9.2.1.2. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
9.2.1.3. Analysis by Scale of Operation
9.2.2. Analysis by Location of Plasma Fractionation Facility
9.2.3 .Analysis by Location of Headquarters
9.3. Concluding Remarks
10. MARKET SIZING AND OPPURTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035
10.3.1. Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035
10.3.1.1. Plasma Fractionation Market for In-house Manufacturers, 2023-2035
10.3.1.2. Plasma Fractionation Market for Contract Service Providers, 2023-2035
10.3.2. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035
10.3.2.1. Plasma Fractionation Market for Preclinical, 2023-2035
10.3.2.2. Plasma Fractionation Market for Clinical, 2023-2035
10.3.2.3. Plasma Fractionation Market for Commercial, 2023-2035
10.3.3. Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035
10.3.3.1. Plasma Fractionation Market for Albumins, 2023-2035
10.3.3.2. Plasma Fractionation Market for Coagulation Factors, 2023-2035
10.3.3.3. Plasma Fractionation Market for Immunoglobulins, 2023-2035
10.3.3.4. Plasma Fractionation Market for Protease Inhibitors, 2023-2035
10.3.3.5. Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035
10.3.4. Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035
10.3.4.1. Plasma Fractionation Market for Hematological Disorders, 2023-2035
10.3.4.2. Plasma Fractionation Market for Hepatic Disorders, 2023-2035
10.3.4.3. Plasma Fractionation Market for Immunological Disorders, 2023-2035
10.3.4.4. Plasma Fractionation Market for Neurological Disorders, 2023-2035
10.3.4.5. Plasma Fractionation Market for Other Disorders, 2023-2035
10.3.5. Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035
10.3.5.1. Plasma Fractionation Market in North America, 2023-2035
10.3.5.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.5.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.5.4. Plasma Fractionation Market in Rest of the World, 2023-2035
10.3.6. Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035
10.3.6.1. Plasma Fractionation Market in North America, 2023-2035
10.3.6.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.6.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.6.4. Plasma Fractionation Market in Rest of the World, 2023-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
